![Ambaw Bellete](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ambaw Bellete
Presidente presso
OncoSTING LLC
Patrimonio netto: - $ in data 31/05/2026
Profilo
Ambaw Bellete is currently Chairman at OncoSTING LLC and Director at Axiom REACH Foundation.
Former roles include President & Chief Operating Officer at CG Oncology, Inc. (2023–2026), Chief Executive Officer at Lion Healthcare Strategies LLC (2021–2023), Head-US Cancer Commercial Operations at Photocure ASA, Trustee at BioNJ, Inc., President at MCS, Inc. (2012–2019), Chief Operating Officer at FerGene, Inc., and President at Photocure, Inc. (2012–2019).
Education includes undergraduate studies at Murray State University (Kentucky).
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 15/04/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Posizioni attive di Ambaw Bellete
| Società | Posizione | Inizio |
|---|---|---|
OncoSTING LLC
 OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma. | Presidente | - |
Precedenti posizioni note di Ambaw Bellete
| Società | Posizione | Fine |
|---|---|---|
| CG ONCOLOGY, INC. | Presidente | - |
Photocure, Inc.
 Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company | Presidente | 01/08/2019 |
MCS, Inc.
 MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry | Presidente | 01/07/2019 |
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Presidente | - |
Formazione di Ambaw Bellete
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
10
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
MCS, Inc.
MCS, Inc. Information Technology ServicesTechnology Services Provides information systems and services to the home health care industry | Technology Services |
Photocure ASA
 Photocure ASA Medical SpecialtiesHealth Technology Develops and sells pharmaceuticals and medical devices | Health Technology |
Murray State University (Kentucky)
 Murray State University (Kentucky) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services Promotes the biotechnology industry in New Jersey | Commercial Services |
CG Oncology, Inc.
 CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Photocure, Inc.
Photocure, Inc. Hospital/Nursing ManagementHealth Services Operates as a bladder cancer company | Health Services |
FerGene, Inc.
FerGene, Inc. BiotechnologyHealth Technology Develops gene therapies for the treatment of unresponsive non-muscle invasive bladder cancer | Health Technology |
OncoSTING LLC
OncoSTING LLC OncoSTING LLC is an American biotechnology company focused on developing immunotherapies for bladder cancer and certain solid tumors. The company is located in the US. Its lead product, OS-151, is a second-generation, recombinant BCG-based therapy that combines traditional BCG immunotherapy with sustained delivery of potent STING agonists. This dual-action approach is intended to enhance efficacy while reducing adverse events compared to standard BCG treatment. OS-151 is being developed primarily for non-muscle invasive bladder cancer and as an intratumoral immunotherapy for tumors such as malignant melanoma. |
